Business
Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together
In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib
About this update from Tempest Therapeutics, Inc.
[{"type":"text","content":"In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495 anti-tumor response shown to be both immune dependent and immune independent Preclinical findings support previously reported Phase 1 clinical results for TPST-1495 showing tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab BRISBANE, Calif., July 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, announced today that in vivo and in vitro data on the unique mechanism of TPST-1495, the company’s novel dual receptor inhibitor of prostaglandin E2 (PGE2) signaling, were published in Cancer Research Communications, a journal of the American Association for Cancer Research. “While the biology of PGE2 in promoting tumor growth and immune suppression is well established, there are still no approved drugs for cancer that effectively block the prostaglandin pathway,” said Tom Dubensky, Ph.D., president of Tempest. “Our innovation with TPST-1495 shows for the first time the effect of blocking PGE2 signaling through the EP2 and EP4 pro-tumor receptors while maintaining the important anti-tumor signaling of PGE2 through the EP1 and EP3 receptors, which could be an important advance to inhibiting PGE2. Additionally, these results further support what we believe is an innovative and robust pipeline at Tempest that includes TPST-1120, a novel PPAR⍺ antagonist, which has shown early positive data from an ongoing global randomized study in first-line HCC patients.” About TPST-1495 Described in the Cancer Research Communications publication, TPST-1495 is an orally-available and potent small molecule designed to block the receptors EP2 and EP4 in the prostaglandin pathway. PGE2 both promotes tumor cell growth and has strong immune-suppressive signaling through these receptors. Several malignancies are thought to be prostaglandin driven through expression of high levels of COX-2, the cellular enzyme that produces PGE2, including endometrial, bladder, breast, colorectal, and cervical cancers. Tempest has conducted multiple studies with peripheral blood mono...